2/2/2023  4:47:41 PM Chg. +0.03 Volume Bid4:47:41 PM Ask4:47:41 PM Market Capitalization Dividend Y. P/E Ratio
2.12EUR +1.44% 35,801
Turnover: 75,494.81
2.12Bid Size: 1,400 2.13Ask Size: 1,400 50.6 mill.EUR 0.00% -

Business description

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

Management board & Supervisory board

Prof. Dr. Dolores J. Schendel
Management board
Axel-Sven Malkomes
Supervisory board
Dr. Gerd Zettlmeissl, Antoinette Hiebeler-Hasner, Dr. Anthony Man, Dr. Frank Mathias, Dr. Keith Manchester, Ronald Scott

Company data

Name: Medigene AG
Address: Lochhamer Str. 11,D-82152 Planegg/Martinsried
Phone: +49-89-200033-0
Fax: +49-89-200033-2920
E-mail: medigene@medigene.com
Internet: www.medigene.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 85.50%
IPO date: 6/30/2000

Investor relations

Name: Dr. Anna Niedl
IR phone: +49-89-200033-3301
IR Fax: -
IR e-mail: investor@medigene.com

Main Shareholders

Tongyang Networks Co.
QVT Financial, L.P.